Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children

Andrew D.J. Pearson(Pearson (United Kingdom)), Gilles Vassal(Université Paris-Saclay), Patrick A. Brown(Haemonetics (United States)), Giovanni Lesa(European Medicines Agency), Aundrietta D. Duncan(Io Therapeutics (United States)), Kimberly Stegmaier(Broad Institute), Scott A. Armstrong(Courant Institute of Mathematical Sciences), Michael J. Kelly(Binghamton University), Amy Barone(United States Food and Drug Administration), Michael L. Meyers(Eastern Cooperative Oncology Group), Joe McDonough(Andrew McDonough B+ Foundation), Ira Jacobs(University of Toronto), Franca Ligas(European Medicines Agency), Gregory H. Reaman(National Cancer Institute), Delphine Heenen(Anticancer Fund), Tilmann Taube(Boehringer Ingelheim (Germany)), Brian Gadbaw(Novartis (United States)), Miguel N. Rivera(University of North Texas), Susan Weiner, Malcolm A. Smith(National Cancer Institute), Elizabeth Fox(Children's National), Adrian M. Senderowicz, Mark W. Kieran(Children Cancer Hospital), Martha Donoghue(Center for Drug Evaluation and Research), Peter C. Adamson(University College London), Dominik Karres(European Medicines Agency), Daniel D. De Carvalho(University Health Network), Nada Jabado(McGill University), Donna Ludwinski(Solving Kids' Cancer), Koen Norga(Vlaams Instituut voor Biotechnologie), Maureen M. Hattersley(AstraZeneca (United States)), Lynley V. Marshall(Royal Marsden Hospital), Zariana Nikolova(Bristol-Myers Squibb (Switzerland)), Peter Ho(Epizyme (United States)), Christian Baumann(GlaxoSmithKline (United States)), Franck Bourdeaut(Institut Curie), Samuel C. Blackman, Victoria Buenger(Coalition Against Childhood Cancer)
European Journal of Cancer
September 26, 2020
Cited by 25


Related Papers